Fragility of Randomized Clinical Trials of Systemic Lupus Erythematosus and Lupus Nephritis Therapies (ACR Convergence 2023) - Sep 24, 2023 - Abstract #2339; Pres time: Nov 14, 2023; 09:00 AM - 11:00 AM; Location: Poster Hall; in person; "The lowest FI was for the ILLUMINATE-2 trial (score: 2, Tabalumab), and the highest FI was found in the BLISS-52 trial (score: 17, Belimumab). The lowest RFI (non-significant trials) was for the ILLUMINATE-1 trial (score: 4, Tabalumab), and the highest RFI was for the TULIP-1 trial (score: 27, Anifrolumab)...Voclosporin trial (AURORA-1) had an FI score of 15...The lowest FQ scores were found in the ILLUMINATE trials and the highest in the Rituximab trials (LUNAR & EXPLORER) and the early terminated LOTUS trial... The evidence supporting the recent approval of therapies for patients with SLE and LN is derived mostly from fragile RCTs, both among trials that met thresholds for statistical significance and among those that did not. G. Figueroa-Parra:; M. Putman: AbbVie/Abbott, 12, Trial participation, AstraZeneca, 12, Trial participation, Novartis, 2; A. Duarte-Garcia: ."
Clinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus
|
|
Gabriel Figueroa-Parra1; Mike Putman2; Ali Duarte-Garcia3
|